Jonathan Violin - Apr 1, 2022 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role: Chief Executive Officer, Director
Signature: /s/ Lara Meisner, Attorney-in-Fact for Jonathan Violin
Stock symbol: VRDN
Transactions as of: Apr 1, 2022
Transactions value $: -$567,636
Form type: 4
Date filed: 4/5/2022, 06:09 PM
Previous filing: Mar 3, 2022
Next filing: May 4, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VRDN	Common Stock	Sale	-$499K	-26.4K	-4.62%	$18.92	545K	Apr 1, 2022	Direct	F1
transaction	VRDN	Common Stock	Sale	-$68.1K	-3.6K	-0.66%	$18.93	541K	Apr 4, 2022	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.34 to $19.43. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2	This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.64 to $19.16. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Content

This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.34 to $19.43. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.64 to $19.16. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.